Please assess the completion status of the following clinical trial:

Trial Title: Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia according to the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition)~* Low level of Extra-pyramidal symptoms~* No clinically significant findings on physical examination~Exclusion Criteria:~* Diagnosis of schizoaffective or schizophreniform disorders~* Any significant psychiatric or neurological disease other than schizophrenia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AZD0328 low dose
- 2 (Type: EXPERIMENTAL): AZD0328 Optimal dose
- 3 (Type: EXPERIMENTAL): AZD0328 High dose
- 4 (Type: PLACEBO_COMPARATOR): Placebo Comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).